Clik here to view.
Federal Circuit Denies Hospira’s Petition to Rehear Safe Harbor Ruling in...
The Federal Circuit has declined to reconsider its December 2019 affirmance of the district court ruling in the Amgen v. Hospira (epoetin alfa) dispute. As we have previously reported, that ruling...
View ArticleClik here to view.
Motion to Dismiss Denied in Amgen v. Hospira BPCIA
At the end of last month, Judge Connolly denied defendants Hospira and Pfizer’s motion to dismiss following a telephone conference with the parties. We previously reported back in February 2020 that...
View ArticleClik here to view.
Amgen v. Hospira Pegfilgrastim Case Stayed Pending Potential Summary Judgment...
On June 16, 2021, the District Court for the District of Delaware issued a claim construction order construing a key term in the ongoing patent dispute between Amgen and Hospira over Hospira’s proposed...
View ArticleClik here to view.
Summary Judgment Practice Scheduled in Amgen v. Hospira Pegfilgrastim Case
As we previously reported, Judge Connolly of the District of Delaware stayed the dispute between Amgen and Hospira last month, pending a determination on whether the Court should entertain summary...
View ArticleClik here to view.
Parties in Amgen v. Hospira Filgrastim Litigation Stipulate to Dismissal of...
On September 2, 2021, the parties in the Amgen v. Hospira (D. Del., No. 18-1064) Neupogen®/filgrastim litigation submitted a stipulation and proposed order to dismiss all claims and counterclaims in...
View ArticleClik here to view.
Parties in Amgen v. Hospira Pegfilgrastim Litigation Stipulate to Dismissal...
On March 19, 2022, the parties in the Amgen Inc. v. Hospira Inc. (D. Del., No. 20-201) NEULASTA®/pegfilgrastim litigation submitted a stipulation to dismiss all claims and counterclaims in the...
View Article